Free Trial
NASDAQ:GBIO

Generation Bio Q1 2025 Earnings Report

Generation Bio logo
$0.35 -0.01 (-2.45%)
As of 03:58 PM Eastern

Generation Bio EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Generation Bio Revenue Results

Actual Revenue
$8.72 million
Expected Revenue
$1.70 million
Beat/Miss
Beat by +$7.02 million
YoY Revenue Growth
N/A

Generation Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Generation Bio's Q2 2025 earnings is scheduled for Monday, May 12, 2025

Generation Bio Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Wedbush Keeps Their Buy Rating on Generation Bio (GBIO)
See More Generation Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Generation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Generation Bio and other key companies, straight to your email.

About Generation Bio

Generation Bio (NASDAQ:GBIO) Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

View Generation Bio Profile

More Earnings Resources from MarketBeat